A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
Wednesday will be a cloudy but mild day across southern England and Wales with outbreaks of rain
A diplomat from the North Korean embassy in Kuala Lumpur is being sought over the death of Kim Jong-nam.
The former leader of Hong Kong Donald Tsang has been jailed for 20 months after being convicted of corruption over a luxury apartment.